Single Dose Darbepoetin Alfa is Useful in Reducing Red Cell Transfusions in Leukemic Children Receiving Chemotherapy

Zachariah, Mathew; Elshinawy, Mohamed; Al‐Rawas, Abdulhakim; Bashir, Wafa; El-Beshlawi, Ismail; Tony, Surekha; Wali, Yasser

doi:10.3109/08880018.2013.824527

Cited by 2 publications

(2 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[23] Hence, the fear of adverse impact on overall survival has also been shown to be incorrect by several recent publications. [24][25][26][27][28] Thus, the correct use of ESAs to treat anemia in cancer patients receiving myelosuppressive chemotherapy is appropriate, safe, and beneficial. [29] In order to maximize the benefit for patients, it is recommended to follow published guidelines in general.…”

Section: Discussionmentioning

confidence: 99%

Role of Cresp® in the management of chemotherapy-induced anemia in cancer patients: A real-world clinical practice audit

Biswas

Pandey

Ghadyalpatil

et al. 2020

South Asian J Cancer

View full text Add to dashboard Cite

Introduction: Anemia is a common, underestimated problem in cancer patients receiving myelosuppressive chemotherapy and has significant adverse effect on the quality of life and outcome. Darbepoetin has been shown to be effective in this setting, but controversy surrounds it actual use. Methods: We analyzed prospectively collected clinical practice data of patients receiving darbepoetin in a real-world setting for this retrospective audit. Patients with baseline hemoglobin (Hb) of <11 g/dl were included in this analysis. Their medical records were audited using a predetermined 35-point pro forma. Results: There were a total of 274 patients with advanced cancer receiving myelosuppressive chemotherapy who had baseline Hb <11 g/dl and who were given darbepoetin. Head-and-neck squamous cell carcinoma, lung cancer, and breast cancer were the most common cancers. Their median baseline Hb was 8.9 g/dl which rose to 11.2 g/dl at the end of commenced therapy, along with improved symptomatology. There were no new toxicities, and only two patients required discontinuation of darbepoetin due to toxicity. Conclusion: Darbepoetin is safe and effective in the prevention and management of anemia among patients receiving myelosuppressive chemotherapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Role of Cresp® in the management of chemotherapy-induced anemia in cancer patients: A real-world clinical practice audit

Biswas

Pandey

Ghadyalpatil

et al. 2020

South Asian J Cancer

View full text Add to dashboard Cite

show abstract

“…Further studies are necessary to assess if darbepoetin contributes to improvement of neurological outcomes. Darbepoetin alfa has been used for many years in older pediatric cancer patients to treat chemotherapy-induced anemia, at a recommended dosage of 2.25 μg/kg weekly or 500 μg every 3 weeks subcutaneously (22–24). Dosage of darbepoetin alpha seems to be similar in children with anemia secondary to CKD or to prematurity, but experience is sparse and target hemoglobin are different from other indication, making comparisons difficult.…”

Section: Discussionmentioning

confidence: 99%

Darbepoetin Alfa in Young Infants With Renal Failure: Single Center Experience, a Case Series and Review of the Literature

et al. 2018

View full text Add to dashboard Cite

Background: Anemia treatment in infants with advanced or chronic kidney disease (CKD) represents an important challenge to nephrologists. The use of darbepoetin alfa, a novel erythropoiesis stimulating agent, has largely replaced recombinant human erythropoietin in older children and in adults with CKD. However, studies reporting the use of darbepoetin alfa in infants below 1 year of age are rare.Case presentation: We report the data of three infants with advanced stage kidney failure, aged 1, 4, and 7 months, who were treated with darbepoetin alfa and followed for 18–41 months. Hemoglobin levels increased in all three patients, reaching the target levels of 10.7–12 g/dl by 11, 19, and 22 weeks respectively, without any documented adverse effects. Patients younger than 1 year of age required a larger darbepoetin alfa dosage (ranged from 1.2 to 2.9 μg/kg per month) as compared to older children. A review of the literature found only three studies using darbepoetin alfa successfully in such young infants, with similar dosage and clinical success.Conclusion: In these three patients with advanced kidney disease, darbepoetin alfa was effective in correcting anemia with no observed side effects. It reinforces its potential use in very young patients with advanced CKD.

show abstract

Single Dose Darbepoetin Alfa is Useful in Reducing Red Cell Transfusions in Leukemic Children Receiving Chemotherapy

Cited by 2 publications

References 22 publications

Role of Cresp® in the management of chemotherapy-induced anemia in cancer patients: A real-world clinical practice audit

Role of Cresp® in the management of chemotherapy-induced anemia in cancer patients: A real-world clinical practice audit

Darbepoetin Alfa in Young Infants With Renal Failure: Single Center Experience, a Case Series and Review of the Literature

Contact Info

Product

Resources

About